drugset / Trial / NCT05916573
A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of HSK16149 in subjects with mild, moderate and severe renal impairment compared to the matched control subjects with normal renal function.
Timeline
- Start
- 2022-12-12
- Primary completion
- 2023-02-27
- Completion
- 2023-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK16149 | Unknown | 20 mg | Oral |